Human GM-CSF R alpha Protein, His Tag (SPR verified)

Customer Reviews
Cat. No. / Size
Price
Qty
GRA-H52H7-100ug
$310.00
GRA-H52H7-1mg (500ug X 2)
$2245.00
ETA of in-stock products:2 business days

Product Details

  • Synonym

    GM-CSF R alpha, GM-CSF-R-alpha, GMCSFR-alpha, GMR-alpha, CSF2RA, CSF2R, CSF2RY, CDw116, CD116

  • Source

    Human GM-CSF R alpha, His Tag (GRA-H52H7) is expressed from human 293 cells (HEK293). It contains AA Glu 23 - Gly 320 (Accession # P15509-1).

    Predicted N-terminus: Glu 23

    Request for sequence
  • Molecular Characterization

    GM-CSF R alpha Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 36.4 kDa. The protein migrates as 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    GM-CSF R alpha SDS-PAGE

    Human GM-CSF R alpha, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • Bioactivity-ELISA

     GM-CSF R alpha ELISA

    Immobilized Biotinylated Human GM-CSF, epitope tag free, primary amine labeling (Cat. No. GMF-H8214) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.2 μg/well) plate can bind Human GM-CSF R alpha, His Tag (Cat. No. GRA-H52H7) with a linear range of 0.039-0.313 μg/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     GM-CSF R alpha SPR

    Human GM-CSF R alpha, His Tag (Cat. No. GRA-H52H7) immobilized on CM5 Chip can bind Human GM-CSF, premium grade (Cat. No. GMF-H4214) with an affinity constant of 65.2 nM as determined in a SPR assay (Biacore 8K) (QC tested).

    Protocol
  • Bioactivity-BLI

     GM-CSF R alpha BLI

    Loaded Biotinylated Human GM-CSF, epitope tag free, primary amine labeling (Cat. No. GMF-H8214) on SA Biosensor, can bind Human GM-CSF R alpha, His Tag (Cat. No. GRA-H52H7) with an affinity constant of 23.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

Customer Reviews
Writing Reviews

Background

GM-CSF R alpha(Granulocyte-macrophage colony-stimulating factor receptor subunit alpha) is also known as CSF2RA, CD116, GMR-alpha. Low affinity receptor for granulocyte-macrophage colony-stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells. Hereditary pulmonary alveolar proteinosis (hPAP) is a rare disorder of pulmonary surfactant accumulation and hypoxemic respiratory failure caused by mutations in CSF2RA (encoding the granulocyte/macrophage colony-stimulating factor [GM-CSF] receptor α-chain [CD116]), which results in reduced GM-CSF-dependent pulmonary surfactant clearance by alveolar macrophages.

Recent Advances

 
Drug Development Progress
  • English Name:

    Granulocyte-macrophage colony-stimulating factor receptor subunit alpha

  • Category:

  • Approved Drugs:

    0 Details

  • Drugs in Clinical Trials:

    4 Details

  • Highest Development Stage:

    Phase 3 Clinical

Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background